May 26, 2026 06:01AM
May 26, 2026 06:01AM
Oct 31, 2025 09:54AM
Feb 28, 2024 07:00AM
Nov 3, 2023 07:00AM
Oct 16, 2023 08:06AM
Oct 16, 2023 08:00AM Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
Aug 28, 2023 07:00AM
Aug 2, 2023 07:00AM
May 16, 2023 04:30PM
May 5, 2023 07:00AM
Apr 27, 2023 09:00AM
Apr 27, 2023 09:00AM
Apr 27, 2023 09:00AM Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Nov 17, 2022 07:17AM
Nov 17, 2022 07:15AM
Nov 17, 2022 07:15AM
Aug 3, 2022 06:29AM
Aug 3, 2022 06:29AM
Jul 27, 2022 06:31AM
Jul 27, 2022 06:30AM Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
Jul 27, 2022 06:30AM
May 12, 2022 04:30PM
May 12, 2022 04:30PM
May 12, 2022 04:30PM
May 4, 2022 06:45AM
May 4, 2022 06:45AM
Apr 26, 2022 09:01AM Editas Medicine (EDIT) Granted FDA Rare Pediatric Disease Designation for EDIT-301
Apr 26, 2022 09:00AM
Apr 26, 2022 09:00AM
Apr 11, 2022 09:00AM
Apr 11, 2022 09:00AM
Feb 24, 2022 06:30AM
Feb 24, 2022 06:30AM
Feb 8, 2022 09:19AM Pre-Open Stock Movers 02/08: (VLDR) (EYES) (CHGG) Higher; (SLQT) (GHM) (NVAX) Lower (more...)
Jan 10, 2022 07:00AM
Jan 10, 2022 07:00AM
Dec 20, 2021 07:00AM
Dec 20, 2021 07:00AM
Dec 20, 2021 07:00AM
Sep 13, 2021 08:00AM
Sep 7, 2021 06:19AM Despite a 100%+ Rally Recently, Goldman Reiterates Sell and Sees a 68% Downside Risk in Editas Medicine (EDIT)
Feb 26, 2021 06:53AM
Feb 25, 2021 07:00AM
Feb 25, 2021 07:00AM
Feb 8, 2021 08:01AM
Feb 8, 2021 08:00AM
Feb 8, 2021 08:00AM
Jan 20, 2021 09:20AM Pre-Open Stock Movers 01/20: (APM) (EVLO) (NFLX) Higher; (GEVO) (HSTO) (BLRX) Lower (more...)
Jan 19, 2021 05:44PM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All